Provence Wealth Management Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Provence Wealth Management Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$220K	Buy	+541	New	+$200K	0.12%	154

Other funds holding VRTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Provence Wealth Management Group's VRTX Position: Q4 2023 in Review

Provence Wealth Management Group opened a new position in Vertex Pharmaceuticals (VRTX) in Q4 2023: 541 shares worth $220K. The stake represents 0.12% of the portfolio and ranks #154 among its holdings.

1,440 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

Provence Wealth Management Group held 541 shares of Vertex Pharmaceuticals worth $220K as of Q4 2023.
Vertex Pharmaceuticals was a new Provence Wealth Management Group position in Q4 2023.
Vertex Pharmaceuticals made up 0.12% of Provence Wealth Management Group's portfolio in Q4 2023, its #154 holding.
1,440 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on Provence Wealth Management Group's 13F filing for Q4 2023, filed 6 Feb 2024.